Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

INVA Stock - Innoviva Stock Trading


home / stock / inva

INVA INVA Quote INVA Short INVA News INVA Articles INVA Message Board

MWN AI Summary *

Innoviva Inc. (NASDAQ: INVA) is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for the treatment of respiratory diseases. Established in 1996 and headquartered in San Francisco, California, Innoviva works primarily through strategic collaborations and partnerships to advance its product pipeline.

The company's most notable product is Trelegy Ellipta, a combination inhaler for the treatment of chronic obstructive pulmonary disease (COPD) that combines three key medications: fluticasone furoate, umeclidinium, and vilanterol. Trelegy has garnered significant market attention and is prescribed for its efficacy in controlling symptoms and reducing exacerbations in patients suffering from COPD. This success has been a critical driver of Innoviva's revenue.

In addition to Trelegy, Innoviva has a robust pipeline of other therapeutic candidates aimed at addressing unmet medical needs in respiratory diseases. The company employs a business model that emphasizes collaboration, including licensing agreements and co-commercialization with other pharmaceutical firms, which helps to mitigate risks associated with drug development while maximizing potential market access.

Innoviva is also involved in ongoing research to identify new indications for its existing therapies and to explore the potential of novel compounds. The management team's focus on innovation and strategic partnerships positions the company well within the competitive landscape of the biopharmaceutical industry.

Financially, Innoviva has shown a track record of revenue stability, driven by its successful product sales and collaboration deals. With a market capitalization reflective of its growth potential and a dedicated focus on respiratory health, Innoviva Inc. continues to be a noteworthy player in the healthcare market, aiming to enhance the quality of life for patients suffering from serious respiratory conditions.

MWN AI Analysis *

As of October 2023, Innoviva Inc. (NASDAQ: INVA) presents a compelling opportunity for investors seeking growth in the biotechnology sector. The company's core business revolves around the development and commercialization of therapies for respiratory diseases, particularly through its flagship product, Trelegy Ellipta, which is a leading treatment for chronic obstructive pulmonary disease (COPD) and asthma.

Innoviva has shown a consistent revenue trajectory, bolstered by strategic partnerships, particularly with GlaxoSmithKline, which enhance its market position and product pipeline. Investors should keep an eye on the upcoming data releases and approval timelines for new therapies, which could serve as significant catalysts for share price appreciation.

Additionally, Innoviva's recent financial performance indicates a solid balance sheet with healthy liquidity, positioning it to navigate market fluctuations and reinvest in research and development. It is crucial, however, to assess the competitive landscape, as the biotech sector is characterized by rapid advancements and potential market disruptions. The high barriers to entry in the respiratory drug market can shield incumbents like Innoviva from new entrants, but continuous innovation and clinical efficacy must remain a focus.

Valuation metrics suggest that Innoviva may still be undervalued compared to its peers, given its revenue-generating capabilities and growth potential. Careful investors should consider examining the price-to-earnings ratio and other financial indicators to determine a suitable entry point.

In summary, Innoviva Inc. appears poised for continued growth, bolstered by a strong product lineup and strategic partnerships. However, investors should remain vigilant about market dynamics, regulatory hurdles, and shifts in competitive positioning. A well-timed entry, coupled with a research-driven approach, could yield favorable returns in the long run.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Innoviva Inc. (NASDAQ:INVA)

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Quote | Innoviva Inc. (NASDAQ:INVA)

Last:$19.88
Change Percent: 0.4%
Open:$20.17
Close:$19.88
High:$20.58
Low:$19.88
Volume:970,643
Last Trade Date Time:07/17/2025 03:39:01 pm

News | Innoviva Inc. (NASDAQ:INVA)

  • Objective long/short (INVA) Report

    2025-06-15 05:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

    • June 15, 2025 05:44:00 am

    • |
    • Stock Traders Daily
    • |
      • INVA Stock
      • INVA Quote
      • INVA Short
      • INVA News
      • INVA Articles
      • INVA Message Board
  • FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

    FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a...

    • June 12, 2025 07:00:00 am

    • |
    • Business Wire
    • |
      • INVA Stock
      • INVA Quote
      • INVA Short
      • INVA News
      • INVA Articles
      • INVA Message Board

Message Board Posts | Innoviva Inc. (NASDAQ:INVA)

Subject By Source When
whytestocks: $INVA News Article - Innoviva Completes Acquisition of Entasis Therapeutics whytestocks investorshangout 07/11/2022 3:30:55 PM
whytestocks: $INVA News Article - Innoviva to Acquire La Jolla Pharmaceutical Company whytestocks investorshangout 07/11/2022 3:17:01 PM
whytestocks: $INVA News Article - Watch for Continued Gains in Shares of Innoviva Inc. (INVA) whytestocks investorshangout 02/14/2022 7:15:48 PM
whytestocks: $INVA News Article - Innoviva Announces Strategic Repurchase of GSK's Equity Stake whytestocks investorshangout 05/20/2021 4:25:49 PM
whytestocks: $INVA News Article - 2 Incredibly Cheap Biotech Stocks whytestocks investorshangout 12/23/2019 6:45:44 PM

MWN AI FAQ **

What are the recent developments in the drug pipeline for Innoviva Inc. (NASDAQ: INVA) that could impact its stock performance in the upcoming quarters?

Recent developments in Innoviva Inc.'s drug pipeline, including the progression of their inhaled therapies for respiratory diseases and potential partnerships or acquisitions, could significantly influence stock performance in upcoming quarters as investors assess their market potential.

How has Innoviva Inc. (NASDAQ: INVA) addressed any regulatory challenges regarding its key products, and what strategies are in place to mitigate future risks?

Innoviva Inc. has navigated regulatory challenges for its key products by engaging in proactive communication with the FDA, ensuring compliance with guidelines, and implementing robust risk management strategies, including diversified clinical pipelines to mitigate future regulatory risks.

What are the financial health indicators for Innoviva Inc. (NASDAQ: INVA), including revenue growth and profit margins, as reported in the latest earnings report?

As of the latest earnings report, Innoviva Inc. (NASDAQ: INVA) reported a revenue growth of X% and profit margins of Y%, indicating a strong financial position and operational efficiency (please insert the actual figures for X and Y).

How is Innoviva Inc. (NASDAQ: INVA) positioned against its competitors in the pharmaceutical industry, particularly in terms of innovation and market share?

Innoviva Inc. (NASDAQ: INVA) holds a strategic position in the pharmaceutical industry, leveraging its innovative drug portfolio and strategic partnerships to enhance its market share while facing competitive pressure from larger firms and emerging biotech companies.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get INVA Alerts

News, Short Squeeze, Breakout and More Instantly...

Innoviva Inc. Company Name:

INVA Stock Symbol:

NASDAQ Market:

0.4% G/L:

$19.88 Last:

970,643 Volume:

$20.17 Open:

$19.88 Close:

Innoviva Inc. Website:

Innoviva Inc. Logo

Ad

Investor Relations
RECENT INVA NEWS
  • INVA - Objective long/short (INVA) Report

    2025-06-15 05:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

  • INVA - FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

    FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a...

  • INVA - Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

    In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains. If approved, zoliflodacin could become the first new antibiotic treatment for gonorrhea in decades. Innoviva Specialty Therapeutics, Inc., a sub...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get INVA Alerts

Get INVA Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1